Abstracts tagged "Biomarkers"

Abstract Number: 2125 • 2012 ACR/ARHP Annual Meeting
Response to Methotrexate Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (Vectra^TMDA) Test and DAS28-ESR
J.W.J. Bijlsma¹, M. Verhoef-Jurgens², M.F. Bakker¹, J.W.G. Jacobs¹, F.P.J.G. Lafeber¹, P.M.J. Welsing³, G. Cavet⁴, D. Chernoff⁴ and D.J. Haney⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, F02.127, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Crescendo Bioscience, Inc., South San Francisco, CA
Background/Purpose: The CAMERA II study (Computer Assisted Management in Early RA) demonstrated that the addition of prednisone to a MTX-based tight control strategy increased effectiveness…
Abstract Number: 1177 • 2012 ACR/ARHP Annual Meeting
Talin Is Cleaved and Expressed As a Short Form in Patients with Rheumatoid Arthritis
Kensei Tsuzaka¹, Masako Takao¹, Naoshi Shinozaki² and Jiro Nishida¹, ¹Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan, ²Cornea Center, Ichikawa General Hospital, TDC, Ichikawa, Japan
Methods: Western Blot analysis showed that the N-terminal 32kDa and the C-terminal 15kDa of calpain1 fragment of talin (32kDa and 15kDa short-talin, respectively) was expressed…
Abstract Number: 719 • 2012 ACR/ARHP Annual Meeting
Biomarkers of Pulmonary Hypertension in Patients with Scleroderma: A Case-Control Study
Zsuzsanna H. McMahan¹, Florian Schoenhoff², Jennifer van Eyk³, Fredrick M. Wigley⁴ and Laura K. Hummers⁴, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Department of Cardiovascular Surgery, Berne, Switzerland, ³Johns Hopkins University and Cedars Sinai Medical Center, Los Angeles, CA, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The objective of this study was to evaluate for an association between various biomarkers and the presence or absence of pulmonary hypertension (PH) in…
Abstract Number: 316 • 2012 ACR/ARHP Annual Meeting
The Interleukin-10 (IL-10) Producing Regulatory B Cell (“B10 cell”) Compartment Expands with Disease Activity in Juvenile Dermatomyositis (JDM) and Pediatric-Onset Systemic Lupus Erythematosus (pSLE)
Ioannis Kalampokis¹, Jeffrey A. Dvergsten² and Thomas Tedder³, ¹Immunology and Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ²Pediatrics Division of Pediatric Rheumatology, Duke University Medical Center, Durham, NC, ³Department of Immunology, Duke University Medical Center, Durham, NC
Background/Purpose: pSLE and JDM are multisystem inflammatory diseases, whereas juvenile idiopathic arthritis (JIA) is typically an organ-limited disease. “B10 cells”, a rare subset of human…
Abstract Number: 2668 • 2012 ACR/ARHP Annual Meeting
Interferon and B-Cell Gene Signatures Contribute to Diagnosis of pre-Clinical Rheumatoid Arthritis
Joyce Lubbers¹, Lotte A. van de Stadt², Saskia Vosslamber¹, John G. Wesseling¹, Dirkjan van Schaardenburg² and Cornelis L. Verweij³, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Diagnosis of the preclinical phase of rheumatoid arthritis (pre-RA) allows timely start of treatment with the potential to prevent disease progression. It is known…
Abstract Number: 2579 • 2012 ACR/ARHP Annual Meeting
Novel Autoantibodies to 14-3-3 Eta Are Highly Specific for Rheumatoid Arthritis
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, Vivian P. Bykerk⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: Serum 14-3-3 eta, a protein biomarker that is differentially expressed in rheumatoid arthritis (RA), has been reported to add incrementally to rheumatoid factor (RF)…
Abstract Number: 2128 • 2012 ACR/ARHP Annual Meeting
Matrix Metalloproteinase 3: A Biomarker of Disease Activity in Rheumatoid Arthritis
Sandra Reuter¹, Torsten Matthias² and Bruno Larida³, ¹AIRA e.V., AESKU.KIPP Institute, Wendelsheim, Germany, ²AESKU.Diagnostics GmbH & Co. KG, Wendelsheim, Germany, ³AESKU.DIAGNOSTICS INC, Oakland, CA
Background/Purpose: New biomarkers for monitoring Rheumatoid Arthritis (RA) disease activity and prognosis of progression are urgently needed to individually optimize drug therapy and prevent joint…
Abstract Number: 1151 • 2012 ACR/ARHP Annual Meeting
Low-Dose Methotrexate and the Selective Accumulation of Intracellular Aminoimidazolecarboxamide Ribotide
Ryan S. Funk¹, Leon van Haandel¹, Mara L Becker² and J.S. Leeder¹, ¹Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospital, Kansas City, MO, ²Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO
Background/Purpose: Current evidence suggests that the anti-folate methotrexate (MTX) mediates its anti-inflammatory effects through inhibition of the purine synthesis pathway causing the accumulation of…
Abstract Number: 732 • 2012 ACR/ARHP Annual Meeting
Changes in Subchondral Bone Provide a Sensitive Marker for Osteoarthritis and Its Progression: Results From a Large Osteoarthritis Initiative Cohort
Michael A. Bowes¹, Christopher B. Wolstenholme¹, Devan Hopkinson¹, Graham R. Vincent¹ and Philip G. Conaghan², ¹Imorphics Ltd, Manchester, United Kingdom, ²University of Leeds, Leeds, United Kingdom
Background/Purpose: Change in subchondral bone has been clinically associated with progression of osteoarthritis (OA). Modern image analysis techniques allow accurate, automated identification of bone in…
Abstract Number: 317 • 2012 ACR/ARHP Annual Meeting
Fatty Acid Profiling: Potential New Biomarkers in Juvenile Idiopathic Arthritis (pilot study)
Weng Tarng Cham¹, Enzo Ranieri², Janice Fletcher² and Christina A. Boros³, ¹Paediatric Rheumatology, Women's and Children's Hospital, North Adelaide, SA 5006, Australia, ²Chemical Pathology and Molecular Genetics, SA Pathology, North Adelaide, SA 5006, Australia, ³Paediatrics, University of Adelaide/Women's and Children's Hospital, Adelaide, Australia
Background/Purpose: The prostanoids are a family of biologically active lipids derived from the 20-carbon essential fatty acids (LCPUFA) all of which are involved in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.